NewsINTERNATIONAL IMMUNOPHARMACOLOGYSaturday, May 2, 2026 · May 2, 2026
Inflachromene attenuates monocrotaline-induced pulmonary arterial hypertension by suppressing the HMGB1-TLR4/RAGE-NF-κB signaling pathway.
WHY IT MATTERS
Recent peer-reviewed research on Pulmonary arterial hypertension that may be relevant for patients and caregivers.
Pulmonary arterial hypertension (PAH) is a debilitating and fatal cardiovascular disorder marked by progressive deterioration of pulmonary arterial function, mainly due to structural remodeling. This pathological remodeling is predominantly driven by prolonged inflammatory activity together with dys...
Related conditions
Related news
Int J Circumpolar Health · -222 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.…
Ther Adv Rare Dis · -192 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.…
Health Inf Sci Syst · -192 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.…
J Allergy Clin Immunol Glob · -39 days ago
Emerging trends and research hot spots in inborn error of immunity: A bibliometric perspective
Published in J Allergy Clin Immunol Glob. Alblooshi H et al.…